184.72.135.210
dgid:
enl:
npi:0

Plumonary and Lung (48)

Drug for Non-cystic Fibrosis Bronchiectasis Meets Phase 2 Goals

Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced positive top-line results from its global, randomized, double-blind placebo-controlled Phase 2 WILLOW study evaluating the efficacy, safety, and pharmacokinetics of INS1007 administered once daily in adults with non-cystic fibrosis...

Read More